Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high-throughput sequencing approach.
Louveau B, Nakouri I, Jouenne F, Baroudjian B, Sadoux A, Da Meda L, Osio A, Reinhart F, Robert J, Herms F, Cribier B, Mortier L, Jouary T, Basset Seguin N, Lebbé C, Mourah S, Battistella M. Louveau B, et al. Among authors: da meda l. Br J Dermatol. 2024 Sep 18;191(4):639-641. doi: 10.1093/bjd/ljae233. Br J Dermatol. 2024. PMID: 38836587 No abstract available.
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
Weppler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, Carlino MS, Long GV, Lo SN, Nordman I, Steer CB, Lyle M, Trojaniello C, Ascierto PA, Lebbe C, Sandhu S. Weppler AM, et al. Among authors: da meda l. Eur J Cancer. 2023 Apr;183:109-118. doi: 10.1016/j.ejca.2023.01.016. Epub 2023 Jan 30. Eur J Cancer. 2023. PMID: 36842413
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
Delyon J, Biard L, Renaud M, Resche-Rigon M, Le Goff J, Dalle S, Heidelberger V, Da Meda L, Toullec L, Carcelain G, Mourah S, Caillat-Zucman S, Allain V, Battistella M, Lebbe C. Delyon J, et al. Among authors: da meda l. Lancet Oncol. 2022 Apr;23(4):491-500. doi: 10.1016/S1470-2045(22)00097-3. Epub 2022 Mar 10. Lancet Oncol. 2022. PMID: 35279271 Clinical Trial.
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, Barnabei L, Corneau A, Da Meda L, Allayous C, Baroudjian B, Jebali M, Herms F, Grzelak L, Staropoli I, Calmettes V, Hadjadj J, Peyrony O, Cassius C, LeGoff J, Kramkimel N, Aractingi S, Fontes M, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbé C. Yatim N, et al. Among authors: da meda l. Sci Adv. 2021 Aug 18;7(34):eabg4081. doi: 10.1126/sciadv.abg4081. Print 2021 Aug. Sci Adv. 2021. PMID: 34407944 Free PMC article.
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans.
Beaziz J, Battistella M, Delyon J, Farges C, Marco O, Pages C, Le Maignan C, Da Meda L, Basset-Seguin N, Resche-Rigon M, Walter Petrich A, Kérob D, Lebbé C, Baroudjian B. Beaziz J, et al. Among authors: da meda l. Cancers (Basel). 2021 May 6;13(9):2224. doi: 10.3390/cancers13092224. Cancers (Basel). 2021. PMID: 34066400 Free PMC article.
Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic-pharmacodynamic real-life study.
Goldwirt L, Louveau B, Baroudjian B, Allayous C, Jouenne F, Da Meda L, Vu LT, Sauvageon H, Herms F, Delyon J, Lebbé C, Mourah S. Goldwirt L, et al. Among authors: da meda l. Cancer Chemother Pharmacol. 2021 Sep;88(3):427-437. doi: 10.1007/s00280-021-04299-x. Epub 2021 May 31. Cancer Chemother Pharmacol. 2021. PMID: 34057572
19 results